Safe Prescribing — MCQs

A 67-year-old man attends anticoagulation clinic. He has been on warfarin for 4 years following an unprovoked pulmonary embolism. His INR today is 8.2. He has no signs of bleeding and is clinically well. His INR two weeks ago was 2.6. He reports no changes to medications, diet, or alcohol intake. He has not missed any doses. His regular medications are warfarin 4mg daily (Mon/Wed/Fri/Sat) and 5mg daily (Tues/Thurs/Sun), ramipril 5mg, and atorvastatin 40mg. What is the most appropriate immediate management?

Q184

A 44-year-old woman with type 1 diabetes is being prepared for emergency laparotomy for perforated appendicitis. She is on a variable rate intravenous insulin infusion (VRIII) at 4 units/hour. Her current blood glucose is 11.2 mmol/L and ketones are 0.4 mmol/L. She is receiving 0.9% sodium chloride with 5% glucose and 0.15% potassium chloride at 125ml/hour. The surgical team requests transfer to theatre immediately. What is the most appropriate management of her insulin during anaesthesia and surgery?

Q185

A 52-year-old woman is started on low molecular weight heparin (LMWH) for confirmed deep vein thrombosis. Her weight is 142 kg (BMI 48 kg/m²). She has normal renal function (eGFR 94 ml/min/1.73m²). Which statement regarding her LMWH dosing and monitoring is most accurate?

Q186

A 75-year-old man with type 2 diabetes is admitted with hypoglycaemia. His glucose on admission was 2.1 mmol/L. He was given oral glucose solution and his glucose recovered to 6.8 mmol/L. His current medications include insulin detemir 18 units in the morning and 14 units at bedtime, metformin 1g twice daily, and sitagliptin 100mg once daily. His HbA1c three months ago was 52 mmol/mol. He has had three episodes of hypoglycaemia in the past two weeks. What is the most appropriate medication adjustment?

Q187

A 61-year-old man is on long-term warfarin therapy for recurrent venous thromboembolism associated with Factor V Leiden deficiency. Over the past 6 months, his INR results have shown marked variability despite good reported adherence: INR readings of 1.8, 3.6, 2.1, 4.2, 2.4, 3.8, 2.2. He takes no other regular medications and denies alcohol excess or dietary changes. What is the most appropriate next step in management?

Q188

A 37-year-old woman with type 1 diabetes presents to the emergency department with vomiting and abdominal pain. Her capillary blood glucose is 24.5 mmol/L and ketones are 4.2 mmol/L. Arterial blood gas shows pH 7.22, bicarbonate 11 mmol/L. She is diagnosed with diabetic ketoacidosis. Her usual insulin is insulin degludec 32 units once daily and insulin lispro with meals. What is the correct approach to her basal insulin during DKA management?

Q189

A 48-year-old woman with newly diagnosed atrial fibrillation is being considered for anticoagulation. She has hypertension and type 2 diabetes. Her renal function shows: creatinine 156 μmol/L, eGFR 34 ml/min/1.73m². She weighs 54 kg and is 162 cm tall. Which direct oral anticoagulant (DOAC) regimen requires dose reduction in this patient?

Q190

According to current UK guidance, what is the appropriate target INR range for a patient with antiphospholipid syndrome who has had recurrent venous thromboembolism despite therapeutic anticoagulation?

Safe Prescribing UK Medical PG Practice Questions and MCQs

Question 181: According to the British National Formulary guidance, what is the minimum interval that should be left between switching from warfarin to a direct oral anticoagulant (DOAC) to minimise the risk of bleeding or thrombosis?

A. Start DOAC when INR falls below 2.0 (Correct Answer)
B. Start DOAC when INR falls below 2.5
C. Start DOAC 24 hours after the last warfarin dose
D. Start DOAC 48 hours after the last warfarin dose regardless of INR
E. Start DOAC when INR falls below 3.0

Explanation: ***Start DOAC when INR falls below 2.0*** - According to **BNF guidance**, when transitioning from **warfarin** to a **direct oral anticoagulant (DOAC)**, the INR should be confirmed to be **below 2.0**. - This threshold ensures that the patient is not **over-anticoagulated**, thereby minimizing the **risk of bleeding** when the new anticoagulant is introduced. *Start DOAC when INR falls below 2.5* - An INR of **2.5** is still within the therapeutic range for many warfarin indications, meaning that adding a DOAC at this level would result in **excessive anticoagulation** and a significantly increased **risk of bleeding**. - The specific guideline for a safe transition from warfarin to a DOAC, as per the BNF, is a stricter **INR cutoff of <2.0**. *Start DOAC 24 hours after the last warfarin dose* - Warfarin has a **highly variable half-life** and its anticoagulant effects can persist for several days after discontinuation, depending on individual patient factors. - Starting a DOAC based solely on a **fixed time interval** rather than the **INR** is unsafe, as it ignores individual variability in warfarin clearance and potential for dangerous **drug interactions**. *Start DOAC 48 hours after the last warfarin dose regardless of INR* - Simply waiting 48 hours does not guarantee that the **INR** has fallen to a safe level, especially in patients with impaired liver function or slow metabolism of warfarin. - Clinical practice dictates **objective measurement of the INR** to ensure that warfarin's anticoagulant effect has sufficiently dissipated before initiating a DOAC, preventing a period of **excessive anticoagulation**. *Start DOAC when INR falls below 3.0* - An INR of **3.0** is well within the **therapeutic range** for many patients on warfarin, such as those with **atrial fibrillation** or **venous thromboembolism (VTE)**. - Initiating a **DOAC** with an INR this high would lead to a substantial overlap of anticoagulant effects, significantly increasing the patient's **risk of major hemorrhage**.

Question 182: A 58-year-old woman with severe psoriasis is started on ciclosporin therapy. According to UK prescribing guidelines, which of the following monitoring parameters should be checked before initiating treatment and every 2 weeks for the first 3 months?

A. Full blood count and liver function tests
B. Blood pressure and serum creatinine (Correct Answer)
C. Thyroid function tests and lipid profile
D. Serum electrolytes and blood glucose
E. Urinalysis and chest radiograph

Explanation: ***Blood pressure and serum creatinine*** - **Ciclosporin** is a calcineurin inhibitor with a significant risk of **nephrotoxicity** and potential to induce **hypertension**. - UK guidelines specifically require these parameters to be checked at baseline and every **2 weeks** for the initial 3 months to identify early adverse effects. *Full blood count and liver function tests* - While ciclosporin can rarely affect **liver function** or **blood counts**, these are not the primary parameters requiring bi-weekly monitoring according to UK guidelines. - More frequent monitoring of **FBC** and **LFTs** is typically associated with drugs like **methotrexate** or **azathioprine** due to risks of myelosuppression and hepatotoxicity. *Thyroid function tests and lipid profile* - **Hyperlipidaemia** can be a side effect of ciclosporin, necessitating **lipid profile** monitoring, but usually at baseline and then at 3-6 month intervals, not bi-weekly. - **Thyroid function tests** are generally not a standard or frequently monitored parameter for patients on ciclosporin therapy. *Serum electrolytes and blood glucose* - Ciclosporin can cause **hyperkalaemia**, **hypomagnesaemia**, and **hyperglycaemia**, so **electrolytes** and **blood glucose** are monitored, but not as frequently as **creatinine** and **blood pressure** in the initial phase. - **Serum creatinine** is the critical parameter for immediate detection of dose-limiting **renal toxicity**. *Urinalysis and chest radiograph* - **Urinalysis** is not a routine bi-weekly monitoring requirement for ciclosporin, unlike for drugs known to cause proteinuria or bladder toxicity. - A **chest radiograph** is not used for monitoring ciclosporin side effects; it may be used for baseline screening for conditions like tuberculosis before initiating some biologics.

Question 183: A 67-year-old man attends anticoagulation clinic. He has been on warfarin for 4 years following an unprovoked pulmonary embolism. His INR today is 8.2. He has no signs of bleeding and is clinically well. His INR two weeks ago was 2.6. He reports no changes to medications, diet, or alcohol intake. He has not missed any doses. His regular medications are warfarin 4mg daily (Mon/Wed/Fri/Sat) and 5mg daily (Tues/Thurs/Sun), ramipril 5mg, and atorvastatin 40mg. What is the most appropriate immediate management?

A. Give oral vitamin K 1-2mg, omit next dose of warfarin, recheck INR in 24 hours
B. Admit for IV vitamin K and prothrombin complex concentrate
C. Continue warfarin but reduce all doses by 1mg, recheck INR in 1 week
D. Give oral vitamin K 5mg, omit warfarin for 2 days, recheck INR in 48 hours
E. Omit warfarin for 2 doses, reduce weekly dose by 10-15%, recheck INR in 3-5 days (Correct Answer)

Explanation: ***Omit warfarin for 2 doses, reduce weekly dose by 10-15%, recheck INR in 3-5 days*** - For an **INR between 4.5 and 10.0** with **no significant bleeding**, the recommended management is to omit 1-2 doses of warfarin and then cautiously reduce the maintenance dose. - This approach allows the INR to gradually decrease back into the therapeutic range without causing overly rapid reversal, which could increase the risk of thrombosis in a patient with a history of **pulmonary embolism**. *Give oral vitamin K 1-2mg, omit next dose of warfarin, recheck INR in 24 hours* - While oral vitamin K can be considered, it is typically reserved for an **INR >10** with no bleeding, or an INR between 5.0-10.0 with a high risk of bleeding. - Administering **oral Vitamin K** to an asymptomatic patient with an INR of 8.2 can lead to a period of **warfarin resistance**, making it difficult to re-establish stable anticoagulation. *Admit for IV vitamin K and prothrombin complex concentrate* - **Intravenous Vitamin K** and **Prothrombin Complex Concentrate (PCC)** are reserved for patients with **serious or life-threatening bleeding** or an extremely high INR (e.g., >20) requiring urgent reversal. - This patient is clinically well with **no signs of bleeding**, making admission and aggressive reversal inappropriate and potentially increasing thrombotic risk. *Continue warfarin but reduce all doses by 1mg, recheck INR in 1 week* - Continuing warfarin with an **INR of 8.2** is unsafe as it significantly increases the **risk of spontaneous hemorrhage**; doses must be omitted. - Rechecking the INR in **one week** is too long for such a highly elevated INR; closer monitoring is required to ensure a safe return to the therapeutic range. *Give oral vitamin K 5mg, omit warfarin for 2 days, recheck INR in 48 hours* - A **5mg dose of oral Vitamin K** is considered high for an asymptomatic patient with an INR of 8.2 and could result in **overshoot** (INR dropping too low), leading to warfarin resistance for several days. - While omitting warfarin for 2 days is a correct step, the addition of such a high dose of Vitamin K is generally not the primary recommendation for an **asymptomatic INR of 8.2**.

Question 184: A 44-year-old woman with type 1 diabetes is being prepared for emergency laparotomy for perforated appendicitis. She is on a variable rate intravenous insulin infusion (VRIII) at 4 units/hour. Her current blood glucose is 11.2 mmol/L and ketones are 0.4 mmol/L. She is receiving 0.9% sodium chloride with 5% glucose and 0.15% potassium chloride at 125ml/hour. The surgical team requests transfer to theatre immediately. What is the most appropriate management of her insulin during anaesthesia and surgery?

A. Continue VRIII and IV fluid infusion throughout surgery with hourly capillary glucose monitoring (Correct Answer)
B. Discontinue VRIII during anaesthesia as she cannot have IV fluids running during surgery
C. Switch to subcutaneous rapid-acting insulin every 2 hours during surgery
D. Reduce VRIII to 1 unit/hour during surgery to minimize hypoglycaemia risk
E. Give stat dose of long-acting insulin subcutaneously and stop VRIII for duration of surgery

Explanation: ***Continue VRIII and IV fluid infusion throughout surgery with hourly capillary glucose monitoring*** - Patients with **Type 1 Diabetes** require a continuous source of insulin to prevent **Diabetic Ketoacidosis (DKA)**, especially during the physiological stress of surgery. - For emergency cases or when the patient is expected to miss more than one meal, a **Variable Rate Intravenous Insulin Infusion (VRIII)** must be maintained intraoperatively with **hourly glucose monitoring**. *Discontinue VRIII during anaesthesia as she cannot have IV fluids running during surgery* - Discontinuing insulin in a Type 1 diabetic will lead to **absolute insulin deficiency** and rapid development of **ketoacidosis**. - Intravenous fluids and infusions are routinely continued during anesthesia via dedicated **venous access** to maintain metabolic stability. *Switch to subcutaneous rapid-acting insulin every 2 hours during surgery* - **Subcutaneous absorption** of insulin is unpredictable during anesthesia due to changes in **peripheral perfusion** and temperature. - **VRIII** is the preferred method because it allows for rapid, titratable adjustments to blood glucose levels in real-time. *Reduce VRIII to 1 unit/hour during surgery to minimize hypoglycaemia risk* - Arbitrarily reducing the rate is dangerous; insulin doses should be adjusted based on **hourly blood glucose** readings and established **sliding scale protocols**. - Given her current glucose of **11.2 mmol/L**, a reduction could lead to worsening **hyperglycemia** during the surgical stress response. *Give stat dose of long-acting insulin subcutaneously and stop VRIII for duration of surgery* - A single dose of **long-acting insulin** lacks the flexibility required to manage the dynamic glycemic changes occurring during a major procedure like a **laparotomy**. - Perioperative management requires the fine-tuned control provided by **intravenous infusion** to keep glucose within the target range (typically 6–10 mmol/L).

Question 185: A 52-year-old woman is started on low molecular weight heparin (LMWH) for confirmed deep vein thrombosis. Her weight is 142 kg (BMI 48 kg/m²). She has normal renal function (eGFR 94 ml/min/1.73m²). Which statement regarding her LMWH dosing and monitoring is most accurate?

A. Dose LMWH using actual body weight up to a maximum of 120 kg
B. Dose LMWH according to ideal body weight to avoid overdosing
C. Dose LMWH according to actual body weight and check peak anti-Xa levels after 3-4 doses (Correct Answer)
D. Dose LMWH using adjusted body weight formula: IBW + 0.4(ABW - IBW)
E. Dose LMWH according to actual body weight and no anti-Xa monitoring is required

Explanation: ***Dose LMWH according to actual body weight and check peak anti-Xa levels after 3-4 doses*** - In patients with **morbid obesity** (BMI >40 kg/m²), LMWH dosing for confirmed DVT should be based on **actual body weight** to ensure adequate therapeutic anticoagulation. - **Peak anti-Xa monitoring** is recommended after the 3rd or 4th dose (when steady-state is achieved) in obese patients to confirm therapeutic levels and prevent clinical failure or toxicity due to altered pharmacokinetics. *Dose LMWH using actual body weight up to a maximum of 120 kg* - Capping the LMWH dose at an arbitrary limit like **120 kg** risks significant **underdosing** in very obese patients, leading to potential treatment failure and recurrent VTE. - Current guidelines generally advocate for initial dosing based on **total body weight** without an empirical cap, followed by laboratory monitoring for confirmation. *Dose LMWH according to ideal body weight to avoid overdosing* - **Ideal body weight** significantly underestimates the volume of distribution for LMWH in obese patients, which often results in **subtherapeutic anticoagulation** and a higher risk of recurrent venous thromboembolism. - This dosing strategy is generally not recommended for therapeutic LMWH in obese individuals. *Dose LMWH using adjusted body weight formula: IBW + 0.4(ABW - IBW)* - While adjusted body weight formulas are used for certain medications with altered pharmacokinetics in obesity, it is **not the standard or preferred method** for therapeutic LMWH dosing in DVT. - Evidence primarily supports using **actual body weight** for initial LMWH dosing for VTE treatment in obese patients, with subsequent anti-Xa monitoring. *Dose LMWH according to actual body weight and no anti-Xa monitoring is required* - Although anti-Xa monitoring is often omitted in normal-weight patients with normal renal function, it is **strongly indicated for extreme body weights** (BMI >40 kg/m² or weight <50 kg). - In a patient with a **BMI of 48 kg/m²**, anti-Xa monitoring is crucial to confirm adequate therapeutic levels, preventing both underdosing (risk of VTE recurrence) and potential excessive anticoagulation (risk of bleeding).

Question 186: A 75-year-old man with type 2 diabetes is admitted with hypoglycaemia. His glucose on admission was 2.1 mmol/L. He was given oral glucose solution and his glucose recovered to 6.8 mmol/L. His current medications include insulin detemir 18 units in the morning and 14 units at bedtime, metformin 1g twice daily, and sitagliptin 100mg once daily. His HbA1c three months ago was 52 mmol/mol. He has had three episodes of hypoglycaemia in the past two weeks. What is the most appropriate medication adjustment?

A. Reduce both insulin detemir doses by 10-20% and continue all oral medications
B. Stop sitagliptin but continue insulin and metformin at current doses
C. Stop insulin completely and manage with metformin and sitagliptin alone given the low HbA1c
D. Reduce bedtime insulin detemir by 20-30% and stop sitagliptin (Correct Answer)
E. Continue all medications but advise more frequent snacking between meals

Explanation: ***Reduce bedtime insulin detemir by 20-30% and stop sitagliptin*** - Recurrent **hypoglycaemia** in an elderly patient with an **HbA1c of 52 mmol/mol** suggests overtreatment, necessitating a significant reduction in the medication carrying the highest risk, such as **basal insulin**. - Stopping **sitagliptin** reduces polypharmacy and complexity while addressing the additive risk it poses when used alongside **insulin**. *Reduce both insulin detemir doses by 10-20% and continue all oral medications* - A minor reduction and continuing all oral medications may be insufficient to prevent further episodes in the context of recent **frequent hypoglycaemia**. - It fails to address the appropriateness of **sitagliptin**, which offers limited benefit in this regimen compared to the risk of **hypoglycaemic events**. *Stop sitagliptin but continue insulin and metformin at current doses* - While stopping sitagliptin is helpful, it does not directly address the likely culprit of the nocturnal or fasting hypoglycemia, which is the **insulin detemir**. - Failing to reduce the **insulin dose** leaves the patient at high risk for immediate recurrence of severe **hypoglycaemia**. *Stop insulin completely and manage with metformin and sitagliptin alone given the low HbA1c* - Abruptly stopping **insulin** in a patient who requires it for glycaemic control can lead to rapid **hyperglycaemia** or metabolic instability. - The HbA1c of 52 mmol/mol is well-controlled but not low enough to suggest that **insulin** is entirely unnecessary. *Continue all medications but advise more frequent snacking between meals* - This approach is medically unsafe as it treats the symptom rather than the underlying cause of **excessive medication**. - Snacking leads to unwanted **weight gain** and does not provide a sustainable or therapeutic solution for **iatrogenic hypoglycaemia**.

Question 187: A 61-year-old man is on long-term warfarin therapy for recurrent venous thromboembolism associated with Factor V Leiden deficiency. Over the past 6 months, his INR results have shown marked variability despite good reported adherence: INR readings of 1.8, 3.6, 2.1, 4.2, 2.4, 3.8, 2.2. He takes no other regular medications and denies alcohol excess or dietary changes. What is the most appropriate next step in management?

A. Switch to a direct oral anticoagulant (DOAC) to avoid the need for monitoring
B. Refer to anticoagulation clinic for review of dosing schedule and consideration of pharmacogenetic testing (Correct Answer)
C. Add low-dose aspirin to provide consistent antiplatelet effect while reducing warfarin dose
D. Continue current warfarin dose but increase monitoring frequency to weekly
E. Prescribe vitamin K 1mg oral supplement daily to stabilize INR

Explanation: ***Refer to anticoagulation clinic for review of dosing schedule and consideration of pharmacogenetic testing*** - Marked **INR variability** despite reported adherence, no other medications, alcohol excess, or dietary changes, strongly indicates a need for **specialist evaluation** to identify subtle factors or underlying causes. - **Pharmacogenetic testing** for **CYP2C9** and **VKORC1** polymorphisms is crucial in cases of unexplained warfarin instability, as these genetic variations significantly affect warfarin metabolism and sensitivity. *Switch to a direct oral anticoagulant (DOAC) to avoid the need for monitoring* - While **DOACs** are effective, the immediate priority is to understand the cause of the **unstable INR** with warfarin. Switching without investigation might lead to similar issues or mismanage a potentially identifiable problem. - This patient has **Factor V Leiden**, and although DOACs are generally suitable, directly switching does not address the physiological reason for the current **erratic anticoagulation control**. *Add low-dose aspirin to provide consistent antiplatelet effect while reducing warfarin dose* - Adding **aspirin** to an unstable warfarin regimen significantly increases the **risk of bleeding** due to additive antiplatelet effects, without addressing the underlying **INR instability**. - **Aspirin** provides antiplatelet activity, which is not a substitute for the **anticoagulant effect** of warfarin needed for recurrent VTE associated with Factor V Leiden. *Continue current warfarin dose but increase monitoring frequency to weekly* - Increasing **monitoring frequency** merely tracks the fluctuations more often but does not provide a **solution** or diagnosis for the inherent instability in warfarin response. - Frequent dose adjustments based on weekly monitoring in an unstable patient can lead to a

Question 188: A 37-year-old woman with type 1 diabetes presents to the emergency department with vomiting and abdominal pain. Her capillary blood glucose is 24.5 mmol/L and ketones are 4.2 mmol/L. Arterial blood gas shows pH 7.22, bicarbonate 11 mmol/L. She is diagnosed with diabetic ketoacidosis. Her usual insulin is insulin degludec 32 units once daily and insulin lispro with meals. What is the correct approach to her basal insulin during DKA management?

A. Stop insulin degludec and manage with fixed-rate intravenous insulin infusion (FRIII) alone
B. Continue insulin degludec at usual dose alongside fixed-rate intravenous insulin infusion (Correct Answer)
C. Reduce insulin degludec to 50% of usual dose alongside fixed-rate intravenous insulin infusion
D. Give insulin degludec only if FRIII is interrupted or discontinued
E. Switch from insulin degludec to insulin glargine at 80% of the dose alongside FRIII

Explanation: ***Continue insulin degludec at usual dose alongside fixed-rate intravenous insulin infusion***- Current clinical guidelines recommend continuing **long-acting basal insulin** (e.g., degludec, glargine, or detemir) at the patient's **usual dose and timing** during DKA management.- This practice ensures **basal insulin coverage** is maintained, which facilitates a smoother transition back to subcutaneous insulin and prevents **rebound ketosis** or hyperglycemia once the IV infusion is stopped.*Stop insulin degludec and manage with fixed-rate intravenous insulin infusion (FRIII) alone*- Stopping basal insulin is an outdated practice that increases the risk of **metabolic instability** during the transition off the insulin pump or IV line.- Without background basal insulin, there is a significant delay in achieving therapeutic levels once the **short-acting IV insulin** is discontinued.*Reduce insulin degludec to 50% of usual dose alongside fixed-rate intravenous insulin infusion*- Arbitrarily reducing the basal insulin dose can result in **sub-therapeutic levels**, complicating the resolution of ketosis and glycemic control.- The **fixed-rate intravenous insulin infusion (FRIII)** is titrated to treat the acute DKA, while the usual basal dose simply maintains the established **physiologic baseline**.*Give insulin degludec only if FRIII is interrupted or discontinued*- Insulin degludec has a **long half-life** (approximately 25 hours); waiting until the FRIII is stopped would lead to a period without adequate insulin coverage.- To be effective for the transition, the medication must be given continuously to maintain **steady-state concentrations** in the bloodstream.*Switch from insulin degludec to insulin glargine at 80% of the dose alongside FRIII*- There is no clinical indication to switch between **basal analogues** during acute DKA management if the patient is already established on a regimen.- Changing the insulin type and dose simultaneously introduces unnecessary **complexity and risk** of prescribing errors during an emergency stabilization.

Question 189: A 48-year-old woman with newly diagnosed atrial fibrillation is being considered for anticoagulation. She has hypertension and type 2 diabetes. Her renal function shows: creatinine 156 μmol/L, eGFR 34 ml/min/1.73m². She weighs 54 kg and is 162 cm tall. Which direct oral anticoagulant (DOAC) regimen requires dose reduction in this patient?

A. Apixaban 5mg twice daily should be reduced to 2.5mg twice daily
B. Rivaroxaban 20mg once daily should be reduced to 15mg once daily
C. Edoxaban 60mg once daily should be reduced to 30mg once daily
D. Dabigatran 150mg twice daily should be reduced to 110mg twice daily
E. All of the above DOACs require dose reduction in this patient (Correct Answer)

Explanation: ***All of the above DOACs require dose reduction in this patient*** - This patient warrants dose reduction for all listed options due to her **moderate renal impairment** (eGFR 34 ml/min/1.73m²) and **low body weight** (54 kg). - Dose adjustments are critical in AF management to balance **stroke prevention** against the high risk of **major bleeding** associated with drug accumulation. *Apixaban 5mg twice daily should be reduced to 2.5mg twice daily* - Dose reduction is required if a patient meets two of the following: **age ≥80**, **weight ≤60kg**, or **creatinine ≥133 μmol/L**; she meets both the weight and creatinine criteria. - Using the standard dose in this patient would significantly increase the risk of **dose-dependent hemorrhage** due to decreased renal clearance. *Rivaroxaban 20mg once daily should be reduced to 15mg once daily* - For patients with a **Creatinine Clearance (CrCl)** between **15-49 ml/min**, the dose must be reduced to 15mg to maintain safety. - Her **eGFR of 34** places her firmly within the range where the standard 20mg dose is contraindicated. *Edoxaban 60mg once daily should be reduced to 30mg once daily* - Edoxaban requires a 50% dose reduction if **CrCl is 15-50 ml/min** or if the patient's **body weight is ≤60kg**. - This patient satisfies both the **renal function** and **weight-based** criteria, making the 30mg dose the only appropriate choice. *Dabigatran 150mg twice daily should be reduced to 110mg twice daily* - Although often weight-independent, Dabigatran dose reduction is recommended when the **eGFR/CrCl is 30-50 ml/min** or if there is an **increased bleeding risk**. - Her renal function (eGFR 34) falls below the threshold for the standard 150mg dose, requiring a step down to **110mg twice daily**.

Question 190: According to current UK guidance, what is the appropriate target INR range for a patient with antiphospholipid syndrome who has had recurrent venous thromboembolism despite therapeutic anticoagulation?

A. 2.0-3.0
B. 2.5-3.5
C. 3.0-4.0 (Correct Answer)
D. 3.5-4.5
E. Target INR is not applicable; switch to DOAC therapy

Explanation: ***3.0-4.0*** - For patients with **antiphospholipid syndrome (APS)** who experience **recurrent venous thromboembolism (VTE)** despite therapeutic anticoagulation (typically INR 2.0-3.0), current UK guidelines recommend increasing the **target INR to 3.0-4.0**. - This higher intensity anticoagulation aims to prevent further thrombotic events, especially in cases of **arterial thrombosis** or persistent VTE on standard therapy. *2.0-3.0* - This range represents the **standard intensity** anticoagulation for initial VTE events or stable APS without a history of recurrent thrombosis. - It is deemed **insufficient** for patients who have already experienced breakthrough VTE while adequately anticoagulated within this range. *2.5-3.5* - While this target INR might be considered in specific circumstances, such as some **mechanical prosthetic heart valves**, it is not the primary recommended intensified target for recurrent APS-related VTE in current UK guidelines. - The specific recommendation for recurrent VTE in APS points towards a higher target range to ensure adequate antithrombotic protection. *3.5-4.5* - This very high INR range significantly increases the **risk of major bleeding** complications without clear evidence of superior efficacy over the 3.0-4.0 range for recurrent APS-related VTE. - Such aggressive anticoagulation is typically avoided due to the unfavourable **risk-benefit profile** in most clinical scenarios. *Target INR is not applicable; switch to DOAC therapy* - **Direct oral anticoagulants (DOACs)** are generally **not recommended** in patients with high-risk APS, particularly those who have experienced recurrent thrombosis or arterial events. - Evidence, including the **TRAPS trial**, suggests that DOACs may be associated with a **higher rate of recurrent thrombosis** compared to warfarin in certain APS populations, especially those with triple antibody positivity.

Practice by Chapter

Anticoagulant safety

Practice Questions

High-risk medicines

Practice Questions

Insulin safety

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free